Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA System
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Operative Pain
Conditions
Post-Operative Pain
Trial Timeline
Feb 1, 2012 → Feb 1, 2013
NCT ID
NCT01539642About Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA System
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA System is a phase 3 stage product being developed by Talphera for Post-Operative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01539642. Target conditions include Post-Operative Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01660763 | Phase 3 | Completed |
| NCT01539642 | Phase 3 | Completed |
Competing Products
18 competing products in Post-Operative Pain